Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy | ||
| dc.conicet.organizacion | Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Biotecnologia Ambiental y Salud. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Biotecnologia Ambiental y Salud. | |
| dc.conicet.organizacion | Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Biotecnologia Ambiental y Salud. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Biotecnologia Ambiental y Salud. | |
| dc.conicet.organizacion | Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Biotecnologia Ambiental y Salud. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Biotecnologia Ambiental y Salud. | |
| dc.contributor.author | Olthoff, Karen Jacqueline | |
| dc.contributor.author | Nigra, Ayelén Denise | |
| dc.contributor.author | Milla Sanabria, Laura Natalia | |
| dc.date.issued | 2024-11 | |
| dc.description.abstract | Background: Glioblastoma (GBM) is the most common and deadly type of brain cancer in adults. Dysregulation of receptor tyrosine kinase pathways, such as the epidermal growth factor receptor (EGFR), contributes to therapeutic resistance. Drugs that inhibit tyrosine kinase activity and monoclonal antibodies against EGFR are strategies used in clinical trials. Photodynamic therapy (PDT) is a tumor treatment that involves the administration of a photosensitizing drug, followed by its activation with visible light, which causes cell death due to oxidative stress. Although PDT helps prolong median survival in patients with GBM, complete remission has not been achieved. Populations of GBM cells have been obtained from the T98G line resistant to PDT with methyl-5-aminolevulinic acid (Me-ALA) for characterization, comparing them with the original parental population. Objective: The objective of this work was to evaluate the general response of T98G GBM cells resistant to PDT when EGFR activity is inhibited with the drug erlotinib. Methods and Results: It has been observed that the administration of the EGFR inhibitor drug in combination with PDT reduced viability (MTT) in resistant populations compared to PDT alone. Furthermore, the PpIX content (flow cytometry) was increased in the resistant population when cells were incubated with Me-ALA and erlotinib. Erlotinib prevented cell proliferation of parental and resistant spheroids. Wound closure was reduced in both parental and PDT-resistant populations. Conclusions: Our results indicate that EGFR activation would be relevant in the resistance of GBM cells to PDT. | es |
| dc.description.fil | Fil: Olthoff, Karen Jacqueline. Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Biotecnologia Ambiental y Salud. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Biotecnologia Ambiental y Salud.; Argentina | |
| dc.description.fil | Fil: Nigra, Ayelén Denise. Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Biotecnologia Ambiental y Salud. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Biotecnologia Ambiental y Salud.; Argentina | |
| dc.description.fil | Fil: Milla Sanabria, Laura Natalia. Universidad Nacional de Rio Cuarto. Facultad de Cs.exactas Fisicoquimicas y Naturales. Instituto de Biotecnologia Ambiental y Salud. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Biotecnologia Ambiental y Salud.; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Olthoff, Karen Jacqueline; Nigra, Ayelén Denise; Milla Sanabria, Laura Natalia; Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy; MDPI; Brain Sciences; 14; 12; 11-2024; 1-16 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 2076-3425 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/259382 | |
| dc.journal.number | 12 | es |
| dc.journal.pagination | 1-16 | es |
| dc.journal.pais | Alemania | es |
| dc.journal.title | Brain Sciences | es |
| dc.journal.volume | 14 | es |
| dc.language.iso | eng | es |
| dc.publisher | MDPI | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2076-3425/14/12/1192 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3390/brainsci14121192 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/2.5/ar/ | * |
| dc.subject | GLIOBLASTOMA | es |
| dc.subject | PHOTODYNAMIC THERAPY | es |
| dc.subject | RESISTANCE | es |
| dc.subject | EGFR | es |
| dc.subject | ERLOTINIB | es |
| dc.subject.classification | Otras Ciencias de la Salud | es |
| dc.subject.classification | Ciencias de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.ab0eeaa8-011f-4177-be17-90f7aef7cb1f_B.pdf
- Tamaño:
- 3.23 MB
- Formato:
- Adobe Portable Document Format